Introduction
Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy (1, 2) . Disease recurrence rates are high, even in patients with microscopically complete (R0) resection (3, 4) . Therefore, vigilant surveillance of all operated patients by regular cross-sectional imaging for several years is essential to facilitate early intervention in case of recurrence (5) (6) (7) . Although the optimal surveillance protocol has yet to be established, a common approach involves three-monthly CT scans (thorax, abdomen, pelvis) in the first two post-operative years, six-monthly CT scans in the next three years and, thereafter, annual scans until 10 years post-operatively (8) . This is associated with considerable costs, repeated radiation exposure and frequent diagnostic ambiguity in early stages of recurrent/metastatic disease (9) . Early detection of disease recurrence is important, as it may allow radical revision surgery in cases of limited metastatic disease volume, or timely initiation of cytotoxic chemotherapy, potentially improving survival (5, 7, (10) (11) (12) (13) . The number of metastatic sites at diagnosis of recurrent disease, as well as time from surgery to detection of recurrence, have been shown to be independent prognostic factors (10, 14) .
Most ACCs are biochemically active, typically presenting a steroidogenic pattern dominated by steroid precursor metabolites rather than end products of steroidogenesis (15) . This pattern has been attributed to the relative dedifferentiation of malignant cells (15, 16) . Most of these steroid precursors, which represent intermediate steps along the three major adrenocortical steroid biosynthetic pathways, are not measured by routine clinical biochemistry. Analysis of 24-h urine collections by gas chromatographymass spectrometry (GC-MS), however, can identify and quantify the metabolites of the large majority of adrenal-derived steroids, providing a truly comprehensive steroid profiling tool (15) . This allows the detection of minute changes in steroidogenesis and the illumination of all intermediate steps that tend to be perturbed in the setting of adrenocortical malignancy. Recent retrospective studies revealed the capacity of urinary steroid profiling to distinguish ACC from benign adrenal tumors. In 2011, our group analyzed steroid metabolite profiles in 24-h collections from 102 patients with benign adrenocortical adenomas and 56 patients with ACC by GC-MS (15) . Machine learning-based analysis of the steroid data identified a distinct malignant e i ' i e i ' for ACC and could differentiate benign from A c c e p t e d M a n u s c r i p t 6 malignant adrenal tumors with a sensitivity and specificity of 90% (15) . Using GC-MS, 95% of ACCs showed evidence of steroid excess, while routine biochemistry only indicated steroid excess in 73% (15) .
Two subsequent retrospective studies also employing GC-MS produced similar results, albeit in smaller cohorts and without the use of machine learning analysis (16, 17) .
In this study, we evaluated the diagnostic performance of urine steroid metabolomics, the combination of mass spectrometry-based steroid profiling and data analysis by machine learning-based algorithms, in the post-operative surveillance of ACC patients following microscopically complete (R0) tumor resection. We assessed the performance of this approach in the detection of disease recurrence, also comparing direct interpretation of steroid profiles by clinical experts to fully automated, machine learning-based analysis of the steroid metabolome. ACC recurrence had to be confirmed by one of the following: a) emergence of new lesions on cross-sectional imaging (CT, MRI), which either enlarge on follow-up scans, or regress in response to systemic antitumor therapy; b) emergence of enhancing lesions on PET or PET-CT scans; or c) histological evidence of recurrent/metastatic ACC from percutaneous biopsy or revision surgery.
Methods

Patients and clinical protocol
Biochemical analysis
Measurement of 24-h urinary steroid metabolite excretion was carried out by gas chromatography-mass spectrometry (GC-MS), as described in detail previously (15) . In brief, free and conjugated steroids were extracted from 1 ml urine by solid-phase extraction. Steroid conjugates were enzymatically hydrolyzed, re-extracted, and chemically derivatized to form methyloxime trimethyl silyl ethers. GC-MS was carried out on an Agilent 5975 instrument operating in selected-ion-monitoring (SIM) mode to achieve sensitive and specific detection and quantification of 19 selected steroid metabolites ( Table 1 ) c i i ei h he i e e i ly e c i e " ali a e i i e i " e a li e indicative of ACC (15) . We did not include glucocorticoid metabolites as these are uninterpretable in mitotane-treated ACC patients, who all receive high-dose glucocorticoid replacement while also being subject to the strong induction of the cortisol-metabolizing enzyme CYP3A4 by mitotane (18) .
Clinical expert review of steroid profiles
Three clinical experts with extensive experience in adrenal disease (I.B., M.O.R., W.A.) were provided with longitudinally collected post-operative urinary steroid profiles from patients who either a) developed disease recurrence (="recurrence cohort") or b) remained recurrence-free over a follow-up period of at least three years, which we considered our "recurrence negative" cohort, as the chances of ACC recurrence past this time-point are low (19) . P i i a lea e a le a a ' i ea e-ee' a e was an essential inclusion criterion for this study; therefore, all included recurred patients had provided at A c c e p t e d M a n u s c r i p t 8 least two post-operative urine samples (one pre-and one post-recurrence). Similarly, we only included patients from the "recurrence-free" cohort who had provided at least two post-operative urine samples for this study part. Pre-operative steroid profiles were provided when available.
The three assessors were blinded to clinical and radiological information other than basic patient demographics (age, sex) and were only provided with a previously established steroid metabolite reference range derived from a healthy adult control cohort (age range 20-81 years; 77 women, 54 men).
The clinical experts were asked t i e i y he i i e i ica i e a ec e ce ( a e " ec e ce" i a ie ha hey c i e e a -recurred), taking into account differences of the e i ile h e e e i heal hy c l a he e i ly e e " ali a e i i e i " i a ie i h a i a y A i i (15) .
Recurrence detection by the clinical experts was considered successful only if based on interpretation of the steroid profile in a urine sample collected before or at the time of the first radiological detection of recurrent disease. This means that late biochemical detection in relation to imaging did not count as true positive for the purposes of sensitivity calculations.
Machine learning-based data analysis
Supervised machine learning was used to create an approach for automatic separation of recurrent from non-recurrent patients (20). The machine learning algorithm was developed by presenting the results of the 19 steroid markers measured by GC-MS in a given 24-h urine, and the corresponding output, i.e. a "yes" or "no" answer to the question whether or not an ACC recurrence had been radiologically detected at the time of urine collection. F he e " ai i " e a le , he al i h lea ed to generalize by finding patterns in the steroid data and use them to provide an output answer when the output is not known.
We used machine learning to approach two separate two-class classification problems. First, we (Matlab documentation, 2018). In order to estimate predictor importance, the parameter that controls computation of predict i a ce a e ' ' ( hi a a e e i calle ' a i ' i Ma la 2015a). The number of decision trees used to obtain the results was 128, which provided optimal trade-off between speed and performance. Ten-fold cross-validation was used to estimate the classifier's predictive quality. In order to account for the differences in the number of samples between the healthy and the recurrence classes, the validation procedure was repeated 50 times for randomized splits of the data. In each run, the healthy class was randomly sub-sampled to make sure that both classes had an equal number of samples.
Statistical analysis
Data analysis and graphic representation was completed using GraphPad Prism Software Version A c c e p t e d M a n u s c r i p t 10
Results
Patient characteristics
We recruited 135 patients (50 men, 85 women) who had undergone complete (R0) resection of a histologically confirmed ACC and provided at least one 24-h urine sample while considered disease-free according to their most recent clinical and radiological assessment and no later than 2 years postoperatively ( Fig. 1) . Median age at diagnosis was 49 years (range 18-80 years).
During a median follow-up period of 32 months (interquartile range (IQR) 15-48 months), 42 of 135 patients (31 %) developed disease recurrence; of these, 10 had to be excluded from the analysis as they had not provided 24-h urines after the detection of recurrence. Of the cohort of patients who remained disease-free post-operatively, 39 were clinically and radiologically followed for more than 3
years; as ACC recurrence presenting beyond that time frame is rare (19), we defined those 39 patients as the "recurrence-free" cohort for the purposes of this study. Relevant clinical details of both cohorts are summarized in Table 2 . The remaining 54 patients without radiological evidence of recurrence but postoperative follow-up <3 years were excluded from further analysis, as they were still at high risk of potentially harboring minimal recurrent disease which had yet to manifest radiologically. of the 32 recurred patients; the remaining six had disease affecting more than one organ ( Table 2) . We classified 15 of the 32 recurrences a 'hi h l e' a he i e he first abnormal imaging, defined as at least one solid-organ lesion 1 cm, and 12 a 'l l e'; five were indeterminate due to incomplete imaging information. We hypothesized that the development of radiologically detectable recurrent or metastatic disease would be heralded by an increase in one or more adrenal steroid metabolites excreted in 24-h urine. Such changes were indeed observed; indicative example cases are shown in heat-map format in Fig. 2B .
An important question here a he he he " ali a e i i e i " e e a a eli e, i.e. in the pre-operative urine at the time of first diagnosis of ACC, represents an inherent characteristic of the individual ACC that is largely preserved upon disease recurrence. We found that this was indeed the case, with re-emergence of steroid metabolites at recurrence mostly identical to those found increased at baseline in the vast majority of patients (Fig. 3A) . The overall six most increased steroids comprised the 11-deoxycortisol metabolite THS, the 11-deoxycorticosterone metabolite THDOC, the pregnenolone and 17-hydroxypregnenolone metabolites 5-PD and 5-PT, as well as the progesterone and 17hydroxyprogesterone metabolites PD and PT (Fig. 3B) . The magnitude of steroid marker elevation, however, was substantially smaller upon disease recurrence than in primary ACCs ( Table 3) , as expected in view of the major differences in disease volume between primary tumor and ACC recurrence (median maximum diameter 92 vs. 11 mm, respectively; Table 2 ).
Expert clinician assessment of steroid profiling results
To evaluate the extent to which incipient steroid profile changes can facilitate diagnosis of recurrent disease, we asked three expert endocrinologists to retrospectively review longitudinal series of urinary steroid profiles individually derived from he ' ec e ce' a ' ec e ce-free' a ie c h . A c c e p t e d M a n u s c r i p t 12 respectively (Fig. 4A ). Of note, eight of the 13 assessed recurrences in these patients were unanimously detected by all three reviewing clinicians. Absence of a pre-operative sample curtailed diagnostic sensitivities to 53% (95%CI 32-73%), 42% (95%CI 23-64%) and 63% (95%CI 41-81%).
The diagnostic performance of the steroid profile review was not altered by adjuvant mitotane treatment (Fig. 4B) . Whether the tumor was found to be hormonally active or not at baseline (on clinical biochemistry) also did not appear to affect the diagnostic performance of the urine steroid metabolome on recurrence (data not shown). Of note, a considerable proportion of correct recurrence detections (ranging from 22-39% for the three experts) were made based on urine collections that pre-dated the first radiological evidence of recurrence by more than 2 months (Fig. 4D) . Only a small number of recurrences were detected later by urine steroid profile interpretation than radiological detection. If late detections were accepted as positive, the overall sensitivities of the clinicians would improve to 75% (95% CI 58-87%), 56% (95% CI 39-72%), and 81% (95% CI 65-91%) for clinicians 1-3, respectively. (Fig. 5A) .
Computational analysis of steroid data
When considering only the first post-recurrence urine sample from each patient in the " ec e ce" c h , the accuracy of Random Forest classification was lower at 75% (AUROC 0.80, 95%
CI 0.75-0.85) ( Fig. 5A) , with the urine of 18 of 32 patients correctly classified as indicative of ACC recurrence (sensitivity 56%, CI 39-72%); in 6 of these patients, recurrence was also detected in samples that preceded the first abnormal imaging. Applying the same diagnostic cut-off, 79% of samples provided y a ie i he ' -ec e ' c h e e correctly identified as non-recurred (false positive rate 21%
[95% CI 16-27%] ).
High-volume recurrences were more likely to be detected by the Random Forest classifier (sensitivity 60% (95% CI 36-80%) vs. 42% (95% CI 19-68%) in low-volume recurrences). However, detection was not affected by mitotane treatment (sensitivity 55% [95% CI 34-74%] in mitotane-treated patients vs. 58% [95% CI 32-81%] in patients not treated with mitotane). Interestingly, in 11 of 18 successfully diagnosed recurred patients, recurrence had also been unanimously detected by all three assessing clinicians, and in 16 of 18 by at least two different clinicians.
The machine learning analysis determined the 11-deoxycortisol metabolite tetrahydro-11deoxycortisol (THS) as the single most important steroid metabolite in differentiating post-recurrence urine samples from samples provided by non-recurred patients, followed by the mineralocorticoid precursor metabolite tetrahydrocorticosterone (THDOC), the pregnenolone metabolite pregnenediol (5-PD) and the androgen metabolite etiocholanolone (Et) (Fig. 5B) .
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Discussion
In this study, we explored the utility of urinary steroid profiling as a novel diagnostic tool for recurrence detection in patients with microscopically complete (R0) resection of ACC. Results show that analysis of the steroid profiling data by a machine learning-based algorithm represents a highly promising non-invasive and radiation-free tool. Once validated prospectively, this would be a useful addition to the current imaging-focused follow-up protocols, expediting scans in patients with suspicious biochemistry and informing discussions in cases with ambiguous imaging results.
Urinary steroid profiling in conjunction with machine learning-based data analysis, also termed urine steroid metabolomics, has already yielded highly promising results in several retrospective studies in patients with primary adrenal masses, where it was employed to differentiate ACCs from benign adrenal tumors (15, 16) . In the distinct clinical setting of post-operative patient surveillance after resection of ACC, the use of urine steroid profiling has only been reported in a few cases (25,26), but has never been systematically investigated.
In the present study, we studied 135 adult patients with microscopically complete R0 resection of ACC recruited from 14 centers associated with the European Network for the Study of Adrenal Tumors (ENSAT). Of the 81 patients who completed three years of post-operative surveillance, 42 (52%) recurred, a rate that is similar to previous retrospective studies (19, 27) , which suggests that our patient cohort is representative of ACC patients routinely seen in clinical practice.
An important finding of our study is that there were substantial similarities between the steroid baseline tissue and blood collection is increasingly becoming routine to support individualized diagnosis and therapy (28) .
We assessed the diagnostic potential of urinary steroid profiling as a recurrence surveillance tool using two approaches: a) a 'e e e ie ' a ach a b) automatic recurrence detection by computational analysis of steroid data using a machine learning-based algorithm. On retrospective, blinded assessment of serial 24-h urine collections, clinicians were able to detect recurrence by the time of its first radiological manifestation with high sensitivity in cases where a pre-operative urine sample was available. In patients who were only able to contribute post-operative urine samples, the ability of clinicians to detect recurrence was substantially lower.
Adjuvant mitotane did not compromise the diagnostic performance of reviewing clinicians, e i e he ' ell c e e a ili y i hi i e i e e i (18) . Mitotane interferes with adrenal steroidogenesis in a number of ways, including a) overall suppression of steroidogenesis resulting in lower excretion values for all steroid metabolites, b) increased glucocorticoid breakdown by induction of CYP3A4, necessitating high-e hy c i e e lace e ; a c) 5α-reductase inhibition, leading to a decrease in 5α-reduced steroids (18) . Although mitotane appeared to blunt the magnitude of the increases in ACC-specific steroid biomarkers in recurred patients, it also suppressed the random sampleto-sample variability, which can be diagnostically helpful. We systematically excluded glucocorticoid metabolites from the steroid analysis, as these would be compromised both by mitotane-induced changes in glucocorticoid metabolism and exogenous hydrocortisone replacement.
We applied a machine learning-based approach to the urinary steroid profiling data to detect recurrent ACC in an automated and defined fashion. The biochemical complexity of steroidogenesis with multiple substrates, products and pathways, in combination with the small underlying disease volumes in the setting of recurrent malignancy, render individual biomarkers diagnostically insufficient. Machine learning-based approaches are ideally suited to systematically evaluate the wealth of data provided by multi-steroid profiling in an objective and reproducible fashion, as already demonstrated in the A c c e p t e d M a n u s c r i p t 16 differential diagnosis of adrenal incidentalomas (15) . Our classifier could distinguish recurred samples from samples provided by non-recurred patients with considerable accuracy. THS was the most important indicator of malignancy, reflecting the pattern of inefficient steroidogenesis in ACC that emerged in previous studies on detection of ACC in patients with adrenal masses (15, 17, 29) . Indeed, all but one of the six steroids that were identified by Random Forest as most differentiating between recurrence and non-recurrence are contained in the e i ly e c i e " ali a e i i e i " i A ( 5) . It should be noted that, unlike assessing clinicians, the computational classifier did not take into account the dynamic longitudinal changes in steroid metabolites in individual patients but judged every sample on its own.
To our knowledge, this is the first study systematically exploring the diagnostic potential of urine steroid profiling in the post-operative monitoring of ACC patients. Strengths of our study include the large cohort size and the application of computational analysis to meet the demands of the multi-variable GC-MS steroid datasets. The limitations of our work pertain to the paucity of pre-operative samples in the majority of patients, the variable frequency of post-operative sample collections and the fact that the machine learning classifier has not been validated on an additional dataset. We also did not systematically compare the results of routine biochemical analysis of serum steroids to the 24-h urine analysis by GC-MS; however, we previously demonstrated that routine serum biochemistry only identified abnormalities in 73% of ACC patients (N=47), while urine steroid metabolomics by GC-MS found abnormalities in 95% (15) .
On this background, and despite the generally small disease volume in the recurred patients, in comparison to patients presenting with a large primary tumors (15) , our approach yielded very promising diagnostic results. Our data indicate that availability of a pre-operative urine and, thus, of the pree a i e " e i i e i " c i e a ly i e he li elih ec e ce e ec i a , therefore, the preservation of a pre-operative 24-h urine sample should be routinely considered, in addition to preservation of serum, plasma and tissue, to facilitate precision medicine. numbers correspond to steroid metabolites as tabulated in Table 1 . recurrence and at least one post-ec e ce i e; N=32) a he ' ec e ce-ee' c h ( a ie i ea e free after 3 years of follow-up; N=39). Where data are not available for the full cohort, number of patients with available data is provided as denominator. N: number, IQR: interquartile range, N/A: not applicable. Table 3 : Quantitation of the increases in the eight urine steroid metabolites previously described as part he " ali a e i i e i " ia ic A (15) , expressed as fold change in comparison to the upper limit of normal (ULN) referring to a healthy adult control cohort. We compared steroid excretion in the pre-operative samples collected with the primary tumor in situ to the first urine samples collected after radiological recurrence detection (= 1 st post-recurrence sample) in the 13 patients with ACC recurrence who provided both pre-and post-operative urine samples. 
Recurred patients (N=32)
Steroids
